

1 **Gingipains from the periodontal pathogen**  
2 ***Porphyromonas gingivalis* play a significant role in**  
3 **regulation of Angiopoietin 1 and Angiopoietin 2 in**  
4 **human aortic smooth muscle cells**

5 **Boxi Zhang \*, Hazem Khalaf, Allan Sirsjö, Torbjörn Bengtsson**

6 Department of Clinical Medicine, School of Health Sciences, Örebro University, Örebro,  
7 Sweden

8 Email address:

9 Boxi Zhang: [boxi.zhang@oru.se](mailto:boxi.zhang@oru.se)

10 Hazem Khalaf: [hazem.khalaf@oru.se](mailto:hazem.khalaf@oru.se)

11 Allan Sirsjö: [allan.sirsjo@oru.se](mailto:allan.sirsjo@oru.se)

12 Torbjörn Bengtsson: [torbjorn.bengtsson@oru.se](mailto:torbjorn.bengtsson@oru.se)

13

14 \* Corresponding authors: Boxi Zhang: Örebro Universitet, Campus USÖ, Klinisk  
15 Forskningscentrum (KFC), Örebro, Sweden. Tel: +46 723706552; Fax: +46 0196026650.  
16 Email: [boxi.zhang@oru.se](mailto:boxi.zhang@oru.se)

17 **Key words:** Angiopoietin 1, Angiopoietin 2, Smooth muscle cells, TNF,  
18 Periodontitis, Atherosclerosis, *Porphyromonas gingivalis*

19

20

21

22

23 **Abstract:**

24 Angiopoietin 1 (Angpt1) and angiopoietin 2 (Angpt2) are the ligands of Tyrosine  
25 kinase (Tie) receptors, and they play important roles in vessel formation and the  
26 development of inflammatory diseases, such as atherosclerosis. *Porphyromonas*  
27 *gingivalis* is a gram-negative periodontal bacterium that is thought to contribute to the  
28 progression of cardiovascular disease. The aim of this study was to investigate the  
29 role of *P. gingivalis* infection in the modulation of Angpt1 and Angpt2 in human  
30 aortic smooth muscle cells (AoSMCs). We exposed AoSMCs to wild type (W50 and  
31 381), gingipain mutant (E8 and K1A), and fimbriae mutant (DPG-3 and KRX-178) *P.*  
32 *gingivalis* and to different concentrations of tumor necrosis factor (TNF). The  
33 atherosclerosis risk factor TNF was used as a positive control in this study. We found  
34 that *P. gingivalis* (wild type, K1A, DPG3 and KRX178) and TNF up-regulated the  
35 expression of Angpt2 and its transcription factor ETS1, respectively, in AoSMCs. In  
36 contrast, Angpt1 was inhibited by *P. gingivalis* and TNF. However, the RgpA/B  
37 mutant E8 had no effect on the expression of Angpt1, Angpt2, or ETS1 in AoSMCs.  
38 The results also showed that ETS1 is critical for *P. gingivalis* induction of Angpt2.  
39 Exposure to Angpt2 protein enhanced the migration of AoSMCs but had no effect on  
40 proliferation. This study demonstrates that gingipains are crucial to the ability of *P.*  
41 *gingivalis* to markedly increase the ratio of expressed Angpt2/Angpt1 in AoSMCs,  
42 which determines the regulatory role of angiopoietins in angiogenesis and their  
43 involvement in the development of atherosclerosis. These findings further support the  
44 association between periodontitis and cardiovascular disease.

## 45 **Introduction**

46 Cardiovascular atherosclerotic disease is a major cause of global morbidity and  
47 mortality. The pathological characteristics of atherosclerosis include inflammation,  
48 proteolysis, and arterial remodeling processes, such as apoptosis and angiogenesis.<sup>1</sup>  
49 Angiogenesis is a prominent feature of atherosclerosis and refers to the growth of new  
50 blood vessels, following an organized genetic program of vascular sprouting, vessel  
51 assembly and organotypic maturation.<sup>2</sup> Tie receptors, together with their  
52 corresponding angiopoietins, have been identified as the signaling system that plays a  
53 particularly central role in vascular remodeling and angiogenesis.<sup>3</sup>

54 There are 4 forms of angiopoietin (Angpt1, Angpt2, Angpt3, and Angpt4) that are  
55 produced by many different types of cells.<sup>4, 5</sup> Through the activation of the Tie2  
56 receptor signaling pathway, angiopoietins regulate vascular maturation, stability and  
57 remodeling.<sup>6</sup> Angpt1 and Angpt2 have opposing effects in the regulation of  
58 inflammatory responses. Angpt1 is an anti-inflammatory regulator, whereas, Angpt2  
59 functions as a pro-inflammatory regulator. Transgenically overexpressed Angpt1 in  
60 mice results in reduced vessel leakiness in response to permeability-inducing  
61 inflammatory agents.<sup>7</sup> Mice without Angpt2 fail to elicit a rapid inflammatory  
62 response and to produce molecules that lead to leukocyte adherence during  
63 stimulation by an inflammatory mediator, such as TNF.<sup>8</sup> In addition to binding to  
64 Tie2, an endothelial-specific receptor, Angpt2 is also able to bind to and activate  
65 integrins in Tie-receptor-negative fibroblasts and breast cancer cells.<sup>9, 10</sup> These

66 findings triggered a new-found interest in analyzing the function of angiopoietins in  
67 non-ECs.

68 *P. gingivalis*, a gram-negative oral anaerobe, has been identified as one of the main  
69 pathogens in the progression of periodontitis and is detected in up to 85% of disease  
70 sites.<sup>11</sup> By interacting with other periodontal pathogens, such as *Filifactor alocis* (*F.*  
71 *alocis*), a gram-positive, obligate anaerobic rod bacterium, *P. gingivalis* plays an  
72 important role in infection-induced periodontal disease.<sup>12, 13</sup> Many epidemiological  
73 studies have shown that severe forms of periodontitis are associated with other  
74 inflammatory diseases, such as rheumatoid arthritis and cardiovascular disease.<sup>14, 15</sup>  
75 The DNA of *P. gingivalis* has been found in coronary stenotic artery plaques of  
76 myocardial infarction patients.<sup>16, 17</sup> In animal models, *P. gingivalis* infection directly  
77 induces and accelerates the formation of coronary and aortic atherosclerosis in pigs and  
78 mice.<sup>18, 19</sup>

79 *P. gingivalis* produces a number of different virulence factors, such as  
80 lipopolysaccharides (LPS), fimbriae, capsule, hemagglutinins and proteases  
81 (gingipains). Gingipains are cysteine proteinases, and they have been divided into two  
82 groups: arginine gingipains (Rgp), which include RgpA and RgpB, and lysine  
83 gingipain (Kgp).<sup>20</sup> The gingipains have been shown to support biofilm formation,  
84 facilitate *P. gingivalis* invasion, and regulate the defensive response processes of host  
85 cells.<sup>21</sup> We and others have demonstrated that gingipains modulate the expression of  
86 several cytokines in multiple cell types, including endothelial cells, gingival fibroblasts,

87 T-cells, and monocytes.<sup>22-25</sup> In addition to gingipains, fimbriae are also important for *P.*  
88 *gingivalis* adhesion to host cells. Many studies have shown that *P. gingivalis* requires  
89 fimbriae to invade endothelial cells<sup>26</sup> and fibroblasts<sup>27</sup>, and to induce the inflammatory  
90 responses.<sup>28, 29</sup>

91 Interestingly, we have previously shown, using microarray techniques, that *P.*  
92 *gingivalis* ATCC 33277 down-regulates the gene expression of Angpt1 while  
93 simultaneously up-regulating the gene expression of Angpt2 in AoSMCs.<sup>30</sup> Smooth  
94 muscle cells (SMCs) are the main components of the vascular wall, and dysfunction  
95 in these cells is directly or indirectly associated with the development of  
96 atherosclerosis.<sup>31</sup> To further investigate the role of different virulence factors of *P.*  
97 *gingivalis* in the modulation of angiopoietins, we infected AoSMCs with wild type  
98 strains (ATCC 33277, W50, 381), gingipain mutants (K1A, E8), or fimbriae mutants  
99 (DPG3, KRX178) of *P. gingivalis*.

100 The aim of this study was to clarify the effects of *P. gingivalis* in regulating the  
101 expression of angiopoietins in AoSMCs.

## 102 **Materials and methods**

103 **Culture of AoSMCs.** Human primary AoSMCs (Invitrogen, Stockholm, Sweden)  
104 were cultured in 231 smooth muscle cell culture medium containing essential growth  
105 supplements (Gibco, Carlsbad, CA). The cells were cultured in 75 cm<sup>2</sup> explant culture  
106 flasks (TPP, Trasadingen, Switzerland) and placed in a cell culture incubator at 37°C

107 with 5% CO<sub>2</sub> and 95% air until confluent. In this study, cells from passage 5 to 10 were  
108 used.

109 **Bacteria culture and preparation.** *F. alocis* ATCC 35896 (CCUG-Culture  
110 Collection, University of Göteborg), *P. gingivalis* ATCC 33277 (American Type  
111 Culture Collection, Manassas, VA), and W50 (wild type) and its isogenic mutant  
112 strains E8 (Rgp mutant strain), K1A (Kgp mutant), and 381 (wild type), were grown in  
113 fastidious anaerobe broth (29.7 g/l, pH 7.2). The *P. gingivalis* 381 corresponding  
114 fimbriae mutant strains DPG3 (major fimbriae mutant) and KRX178 (minor fimbriae  
115 mutant) were grown in fastidious anaerobe broth supplemented with 1 µg/ml  
116 erythromycin. The different *P. gingivalis* strains were grown in an anaerobic chamber  
117 (80% N<sub>2</sub>, 10% CO<sub>2</sub>, and 10% H<sub>2</sub>, at 37°C) (Concept 400 Anaerobic Workstation;  
118 Ruskinn Technology Ltd., Leeds, United Kingdom).

119 After 72 hours of culturing, bacteria were harvested by centrifugation for 10 min at  
120 10000 rpm and then washed and resuspended in Krebs-Ringer-Glucose (KRG) buffer  
121 (120 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO<sub>4</sub>, 1.7 mM KH<sub>2</sub>PO<sub>4</sub>, 8.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 10  
122 mM glucose and 1.1 mM CaCl<sub>2</sub>, PH 7.3).

123 The concentration of *P. gingivalis* was determined by counting CFU (Colony-forming  
124 unit) of different dilutions of bacteria on blood agar after 5 to 7 days. The optical  
125 density (OD) at 600 nm of bacteria suspension was measured with a spectrophotometer  
126 (BioPhotometer plus) (Eppendorf AG, Hamburg, Germany) and was correlated with  
127 the concentration (CFU/ml) of the bacteria.

128 **Gingipain quantification.** The activity of arginine and lysine gingipains from  
129 different strains of *P. gingivalis* were quantified using arginine and lysine substrates  
130 (Peptanova, Sandhausen, Germany). The arginine gingipain substrate peptide  
131 sequence was Boc-Phe-Ser-Arg-AMC (t-Butyloxycarbonyl- L-phenylalanyl- L-seryl-  
132 L-arginine- 4-methylcoumaryl-7-amide) and the lysine gingipain substrate peptide  
133 sequence was Z-His-Glu-Lys-AMC (Benzyloxycarbonyl- L-histidyl- L-glutamyl-  
134 L-lysine- 4-methylcoumaryl-7-amide).  $10^6$  CFU of different strains of washed *P.*  
135 *gingivalis* were incubated with either of the substrates at a final concentration of  
136  $100\mu\text{M}$  for one hour at  $37^\circ\text{C}$ , and the enzyme activity was registered in a  
137 fluorescence microplate reader (Fluostar Optima, Ortenberg, Germany) at  
138 excitation/emission wavelength settings of 380/ 460 nm.

139 **Stimulation of AoSMCs with *P. gingivalis*, LPS and TNF.** AoSMCs were seeded at  
140 a density of 150,000 cells per well in 6-well plates coated with Type I collagen (Gibco,  
141 Carlsbad, CA), Thereafter, cells were serum starved for 24 hour using DMEM medium  
142 (Gibco, Carlsbad, CA) containing 0.5% FBS (Sigma, St. Louis, MO), 2 mM  
143 L-glutamin and antibiotics (Gibco, Carlsbad, CA). After being washed and  
144 resuspended in fresh DMEM medium, AoSMCs were challenged with different strains  
145 of *P. gingivalis* at a concentration of 10 MOI for 2, 8, 16, 24 or 48 hours. Because *F.*  
146 *alocis* was found to co-infect with *P. gingivalis*, AoSMCs infected with *F. alocis* for  
147 24 hours was served as a control in this study. For AoSMCs stimulated with the  
148 fimbriae mutants DPG3 and KRX178, AoSMCs treated with 1  $\mu\text{g/ml}$  of erythromycin  
149 served as control. To determine the role of arginine gingipains, *P. gingivalis*, ATCC

150 33277, W50, and K1A were incubated with 1mM of Leupeptin (Roche Diagnostics  
151 Corporation, USA), which is an arginine gingipain inhibitor, for 1 h prior stimulation  
152 of the AoSMCs. AoSMCs were also stimulated with 10 ng/ml or 50 ng/ml of TNF  
153 (Sigma-Aldrich, St. Louis, MO) or 10 ng/ml or 100 ng/ml of *P. gingivalis* LPS  
154 (InvivoGen, Toulouse, France) for 24 or 48 hours.

155 **Knockdown of ETS1 in AoSMCs.** Knockdown of ETS1 was performed by using  
156 human ETS1 siRNA (Perkin-Elmer Applied Biosystems, Foster City, CA) in 150,000  
157 cells/well 6-well plates. A volume of 4  $\mu$ l of Lipofectamine 2000 (Life Technologies,  
158 Carlsbad, CA) was added to 250  $\mu$ l of Opti-MEM medium (Life Technologies,  
159 Carlsbad, CA) for 5 min, which was then mixed with 250 $\mu$ l of Opti-MEM medium  
160 containing 50 pmol of ETS1 siRNA (VHS40614) (Life Technologies, Carlsbad, CA)  
161 or 50 pmol non-targeting siRNA (Life Technologies, Carlsbad, CA) as a control. After  
162 20 min at room temperature, the transfection mixture was added to each cell culture  
163 well containing 500 ml of Opti-MEM medium and cultures were incubated for 6 h. A  
164 volume of 1ml of antibiotic-free growth medium was then added and cultures were  
165 incubated for another 18 h. The cells were then starved for 24 h and treated with *P.*  
166 *gingivalis* W50 for 24 h.

167 **Quantitative real-time PCR.** Isolation of RNA from AoSMCs was carried out using  
168 a Genejet RNA isolation kit (Fermentas, Sweden). cDNA were synthesized using  
169 equal amounts of RNA and High Capacity cDNA Reverse Transcription Kits  
170 (Perkin-Elmer Applied Biosystems, Foster City, CA) according to the manufacturer's



171 protocol. The primer sequences for Angpt1, Angpt2, ETS1, and Glyceraldehyde  
172 3-phosphate dehydrogenase (GAPDH) (Eurofins, Ebersberg, Germany) used in this  
173 study are listed in table 1. Quantitative real-time PCR for SYBR Green (Fermentas,  
174 Sweden) was performed with an ABI Prism 7900HT Sequence Analyzer. Relative  
175 quantification of gene expression was determined using the  $\Delta\Delta C_t$  method and  
176 normalized by the  $C_t$  value of GAPDH.

177 **Western blot assay.** Proteins were extracted from AoSMCs that had been stimulated  
178 or not stimulated with *F. alocis*, different strains of *P. gingivalis* or TNF for 24 h or 48  
179 h, using RIPA Buffer (Sigma-Aldrich, St. Louis, MO) mixed with a protease inhibitor  
180 cocktail (Sigma-Aldrich, St. Louis, MO). After centrifugation at 10,000 rpm for 10  
181 min, the total protein concentration was determined using a BCA protein assay kit  
182 (Thermo Scientific, Rockford, USA). An equal amount of each sample (30  $\mu$ g) was  
183 electrophoresed on precast SDS-PAGE gels and transferred onto PVDF membrane  
184 (Bio-Rad, Hercules). After blocking in 3% BSA (Sigma-Aldrich, St. Louis, MO) for 1  
185 h, membranes were probed overnight at 4°C with goat polyclonal anti-Angpt2 (R&D  
186 systems, UK) at the concentration of 1 $\mu$ g/ml. Rabbit polyclonal anti-GAPDH at a  
187 1:15000 (Santa Cruz Biotechnology, Dallas, Texas) dilution was used as a loading  
188 control. For Angpt2, blots were incubated with anti-goat IgG (R&D systems, UK) at a  
189 concentration of 1:3000 for 2 h. For GAPDH, blots were incubated with anti-rabbit  
190 IgG (Santa Cruz Biotechnology, Dallas, Texas) at a concentration of 1:15000 for 2 h.  
191 The blots were visualized using Luminata Forte Western HRP substrate (Millipore,  
192 Darmstadt, Germany) and a ChemiDoc MP imager (Bio-Rad, Hercules).

193 Densitometric analysis was performed using Image Lab software (Bio-Rad, Hercules).

194 **Enzyme-linked immunosorbent assay (ELISA).** The supernatants from AoSMCs  
195 that were challenged with the *P. gingivalis* strain of ATCC33277, W50, E8, or K1A  
196 for 24 h or 48 h were collected and centrifugated at 1500×g for 5 min at 4°C.  
197 Thereafter, the supernatants were stored at -80°C until use. TNF was analyzed by  
198 ELISA (Biolegent, San Diego, CA) according to the manufacturer's instructions.

199 **Proliferation assay.** To investigate proliferation responses, serum-starved AoSMCs  
200 were incubated with different concentrations of recombinant human Angpt2 for 24 h,  
201 The medium was then replaced with medium containing 0.5% FBS for 24 h. The  
202 proliferation responses were monitored using an MTT (3-(4, 5-dimethylthiazolyl-2)-2,  
203 5-diphenyltetrazolium bromide) assay. MTT (Sigma-Aldrich, St. Louis, MO) was  
204 dissolved in the cell culture DMEM medium at a concentration of 500 µg/ml. After  
205 different stimulations, the supernatant was aspirated and cells were washed twice with  
206 PBS. Then, 1 ml of MTT medium was added to each well of the plate. After 2h  
207 incubation at 37°C, the medium was removed and MTT was extracted from viable  
208 cells by adding 1 ml DMSO. Measurements of OD absorbance at 540 nm were then  
209 performed in a microtiter plate reader (SpectraMax 340, Microplate Reader; Molecular  
210 Devices Corp., Sunnyvale, CA).

211 **Wound healing assay.** Studies of the regulation of AoSMCs migration by ANGPT2  
212 were performed using a wound-healing assay. AoSMCs were seeded into 6-well  
213 culture plates and starved for 24 h in DMEM medium containing 0.5% FBS. The

214 resulting single cell layer was then carefully wounded using a 100  $\mu$ l pipette tip. Cells  
215 were washed twice with DPBS to remove cellular debris and then 2 ml of DMEM  
216 medium containing 0.5% FBS was added to each well. AoSMCs were then treated with  
217 10 ng/ml, 100 ng/ml, or 500 ng/ml of Angpt2 or DPBS as control. Wounds were  
218 photographed immediately (0 h) and 18 h after wounding with an Olympus inverted  
219 CKX41 phase-contrast microscope. Migration was evaluated by measuring the  
220 reduction in the area of the wound after migration of the cells into the cell-free zone  
221 with the NIH software package Image J (ImageJ 1.32j; NIH, Bethesda, MD).

222 **Statistical Analysis.** Data are expressed as the average  $\pm$  standard error of the mean  
223 (SEM), with  $p < 0.05$  considered to be significant. Student's t-test was used for  
224 statistical comparisons of two groups and One-way ANOVA with Bonferroni or  
225 Dunnett post-tests were used for calculating the statistical significance between  
226 differences in data groups obtained from the real-time qPCR, western blot,  
227 proliferation, and wound healing experiments that have more than two groups.  
228 Statistical analysis was performed using GraphPad Prism software.

## 229 **Results**

230 **Gingipain activity of *P. gingivalis*.** In this study, we used gingipain substrates and a  
231 fluorescence assay to validate the activity of gingipains in different *P. gingivalis*  
232 strains. As expected, E8 showed only Kgp activity and K1A showed only Rgp  
233 activity. There was no clear difference in gingipain activity between the *P. gingivalis*  
234 strains ATCC 33277, W50, 381, DPG3 and KRX178. (Fig. S1A and S1B)

235 ***P. gingivalis* and its gingipains regulate Angpt1 and Angpt2 production in**  
236 **AoSMCs.** mRNA was collected from samples of each different group and assessed by  
237 quantitative real-time PCR for Angpt1 and Angpt2. The results were normalized  
238 against GAPDH. For Angpt1, the gene expression level was significantly inhibited by  
239 wild type *P. gingivalis* ATCC 33277 and W50 after 24 h compared to unstimulated  
240 cells that served as negative control. In contrast, the Rgp-deficient strain E8 had  
241 almost no effect on Angpt1 gene expression in AoSMCs. The Kgp-deficient strain  
242 K1A also significantly inhibited the expression of Angpt1 after 24 h, but to a lesser  
243 extent than the wild type strains (Fig. 1A). Leupeptin only sparsely reversed the  
244 inhibitory effect of wild type *P. gingivalis* on Angpt1, but it completely neutralized  
245 the inhibition of K1A (Fig. S2A).

246 The gene expression of Angpt2 was markedly increased by Wild type *P. gingivalis*  
247 ATCC 33277 after 16 h and 24 h and by W50 after 16 h, 24 h, and 48 h, whereas the  
248 Rgp-deficient strain E8 had no effect on the gene expression of Angpt2. K1A also  
249 increased the expression of Angpt2; however, the results were not significant (Fig.  
250 1B). Inhibition of Rgp with Leupeptin effectively antagonized the stimulatory effect  
251 of wild type and K1A *P. gingivalis* on Angpt2 (Fig. S2B). We also infected AoSMCs  
252 with *F. alocis*, a different bacterial species often found to co-infect with *P. gingivalis*.  
253 However, no significant change was observed in Angpt1 and Angpt2 (Fig. S3) gene  
254 expression compared to control samples after 24 h, which indicates changes to  
255 Angpt1/2 are a result of *P. gingivalis* specifically.

256 Here, we focused on Angpt2 protein expression because the gene expression of  
257 Angpt2 was markedly induced by *P. gingivalis*. AoSMCs were infected with *F. alocis*  
258 or different strains of *P. gingivalis* at a concentration of 10 MOI for 24 h and 48 h.  
259 The *P. gingivalis* ATCC 33277 strain significantly increased the Angpt2 protein  
260 expression in AoSMCs at 24 h (Fig. S4A and S4B) after infection, whereas both  
261 ATCC 33277 and W50 significantly increased Angpt2 protein level at 48 h (Fig. 1C  
262 and 1D) after infection. As expected, the western blot results for 48 h incubations  
263 with the bacteria followed the same trend that was observed for Angpt2 gene  
264 expression.

265 **Fimbriae and LPS are not involved in *P. gingivalis*-mediated regulation of**  
266 **Angpt1 and Angpt2 production in AoSMCs.** We further investigated the role of  
267 fimbriae of *P. gingivalis* in modulating Angpt1 and Angpt2 expression in AoSMCs.  
268 The wild type strain *P. gingivalis* 381 and its corresponding major fimbriae mutant  
269 DPG3 and minor fimbriae mutant KRX178 significantly down-regulated the gene  
270 expression of Angpt1 in AoSMCs after 24h (Fig. 2A). All three of these strains of *P.*  
271 *gingivalis* significantly up-regulated the gene expression of Angpt2 in AoSMCs after  
272 24 h of incubation (Fig. 2B). We next assessed whether changes to Angpt1/2 were a  
273 result of LPS, considering that previous research has demonstrated that the quantity of  
274 LPS produced and released differs between various strains.<sup>25</sup> Stimulation of AoSMCs  
275 with *P. gingivalis* LPS for 24 h or 48 h resulted in no significant changes in Angpt1 or  
276 Angpt2 expression level (Fig. S5A and S5B).

277 **TNF regulates Angpt1 and Angpt2 production in AoSMCs.** AoSMCs were  
278 stimulated with different concentration of TNF for 24 h and 48 h. Gene expression of  
279 Angpt1 was significantly reduced (1.64-fold and 1.87-fold) after stimulation for 24 h  
280 with 10 ng/ml and 50 ng/ml TNF, respectively (Fig. 3A). The levels of Angpt2  
281 mRNA were significantly increased (8.30-fold and 9.67-fold) after stimulation for 24  
282 h with 10 ng/ml and 50 ng/ml TNF, respectively. Similar to our results for the gene  
283 expression of Angpt1, we did not observe a significant change for Angpt2 mRNA  
284 expression levels after 48 h (Fig. 3B). With respect to protein expression, TNF  
285 stimulation induced Angpt2 after 24 h (Fig. S4C and S4D) and 48 h (Fig. 3C and 3D),  
286 with a significant up-regulation induced by stimulation with 50 ng/ml for 48 h.

287 The TNF ELISA kit detects human TNF levels from 7.8 pg/ml to 500 pg/ml.  
288 However, the TNF levels in the supernatants from AoSMCs treated with the *P.*  
289 *gingivalis* strains of ATCC33277, W50, E8, or K1A were undetectable (data not  
290 shown).

291 ***P. gingivalis* and TNF up-regulate ETS1 in AoSMCs.** The wild type strains *P.*  
292 *gingivalis*, ATCC 33277 and W50, significantly increased ETS1 expression in  
293 AoSMCs after 16 and 24 h (Fig. 4A). Compared with W50, the Rgp and Kgp mutant  
294 strains E8 and K1A, respectively, had no effect on ETS1 gene expression. Inhibition  
295 of Rgp with Leupeptin, significantly antagonized the stimulatory effect of W50 (Fig.  
296 S2C). The wild type strain 381 and its fimbriae mutants, DPG3 and KRX178,  
297 significantly increased ETS1 expression in AoSMCs after 24 h (Fig. 4B). TNF also

298 significantly increased the expression of ETS1 in AoSMCs after 24h when applied at  
299 a concentration of 10 ng/ml and 50 ng/ml (Fig. 4C). Compared with wild type *P.*  
300 *gingivalis* and TNF, *F. alocis* showed no effect on ETS1 gene expression after 24 h  
301 (Fig. S3). To ensure that the up-regulation of ETS1 by *P. gingivalis* infection was  
302 correlated with the up-regulation of Angpt2 in AoSMCs, we performed an ETS1  
303 siRNA knock down experiment. We found that the ETS1 siRNA significantly  
304 reduced the up-regulation of ETS1 in AoSMCs that were treated with *P. gingivalis*  
305 W50 (Fig. 5A). This result confirms our finding by showing that the up-regulation of  
306 Angpt2 at the mRNA (Fig. 5B) and protein levels (Fig. 5C and 5D) by W50 is  
307 significantly reduced in ETS1 siRNA knock down AoSMCs.

308 **Regulation of AoSMCs proliferation and migration by Angpt2.** To investigate  
309 how Angpt2 regulates the cellular function of AoSMCs, we studied the proliferation  
310 and migration of AoSMCs after stimulation with Angpt2 protein. The results of MTT  
311 assays showed that Angpt2 has no effect on AoSMCs proliferation (Fig. 6A).  
312 However, Angpt2 protein dose-dependently increased the migration of AoSMCs in  
313 cells analyzed with the scratched assay. After 18 h, cells stimulated with 100 ng/ml or  
314 500 ng/ml of Angpt2 protein covered almost the entire scratched area (Fig. 6B and 6C).

## 315 Discussion

316 Considerable evidence has indicated that periodontal infection is a mild but  
317 significant risk factor for developing cardiovascular disease. The  
318 periodontopathogenic bacteria *P. gingivalis* is considered to be directly or indirectly

319 involved in the development of atherosclerosis and cardiovascular disease. We have  
320 previously reported that *P. gingivalis* causes platelet aggregation, sensitizes platelets  
321 to epinephrine, suppresses the inflammatory responses of immunological cells and  
322 modifies LDL.<sup>32-34</sup>

323 This study indicates that wild type *P. gingivalis* decreases the gene expression level of  
324 Angpt1 but increases the gene and protein expression of Angpt2 in AoSMCs. For  
325 Angpt1, we did not observe significant differences at the protein level. This might be  
326 due to the fluctuations in results observed in Angpt1 gene expression in AoSMCs  
327 infected by *P. gingivalis* at early time points. Endothelial cells, which are stored in the  
328 endothelial-specific Weibel-Palade bodies (WPBs), are the main source of Angpt2.  
329 Certain stimuli, such as hypoxia, thrombin, or phorbol-12-myristate-13-acetate (PMA),  
330 are known to induce the rapid release of Angpt2 from WPBs.<sup>35, 36</sup> We found that  
331 AoSMCs are also able to produce Angpt2. However, although unstimulated AoSMCs  
332 produce Angpt2 at a low level, stimulation with wild type *P. gingivalis* dramatically  
333 increases the gene expression of Angpt2 in AoSMCs. Elevated levels of Angpt2 have  
334 been suggested to be a marker of cardiovascular disease, oral squamous cell carcinoma  
335 and lung cancer.<sup>37-39</sup> These results are also relevant because a high  
336 angiotensin-2/angiotensin-1 ratio is associated with pathogenesis in hemangiomas,  
337 atherosclerosis, and hemorrhagic endometrium.<sup>40, 41</sup>

338 The RgpA/B mutant E8 was unable to alter the expression of Angpt1 or Angpt2 in  
339 AoSMCs. The Kgp mutant K1A down-regulated the expression of Angpt1 and  
340 up-regulated the expression of Angpt2 in AoSMCs, but compared to the wild type,



341 K1A had only small effects on the regulation of these angiopoietins. These results  
342 indicate that gingipains, especially Rgp, play important roles in *P. gingivalis*-induced  
343 modulation of angiopoietins in AoSMCs. In support of this idea, inhibition of Rgp with  
344 Leupeptin antagonized the up-regulation of Angpt2 and the down-regulation of Angpt1  
345 that was induced by *P. gingivalis* infection. The infection of AoSMCs with *F. alocis*,  
346 which has a low cysteine protease activity,<sup>42</sup> had no effect on the expression of Angpt1,  
347 Angpt2, or ETS1. Gingipains are cell surface trypsin-like cysteine proteases that are  
348 produced by *P. gingivalis*. Both Rgp and Kgp are secreted by *P. gingivalis* and are  
349 indispensable for the ability of the bacterium to obtain nutrients from the  
350 environment.<sup>43</sup> Studies have shown that the RgpA/B mutant markedly decreases  
351 hemagglutinating activity, whereas the Kgp mutant only slightly affects  
352 hemagglutinating activity.<sup>44,45</sup> In contrast to RgpB, which only has a catalytic domain,  
353 RgpA and Kgp, contain non-covalent complexes that are composed of separate  
354 catalytic and adhesion/ hemagglutinin domains.<sup>46</sup> These results show that RgpA and  
355 Kgp are important to the ability of *P. gingivalis* to acquire hemagglutinins from the host  
356 cells through proteolytic processing. Moreover, gingipains have the ability to impair  
357 host immune response function through degradation and inactivation of  
358 immunoglobulins, such as IgG, IgA, and secretory IgA,<sup>47</sup> and proinflammatory  
359 cytokines, such as interleukin 6 (IL-6), interleukin 8 (CXCL8), and interleukin-1 $\beta$   
360 (IL-1 $\beta$ ).<sup>48</sup> The results of this study suggest that gingipains, especially Rgp, are  
361 responsible for *P. gingivalis*-mediated regulation of Angpt1 and Angpt2 in AoSMCs.  
362 In contrast to gingipains, fimbriae and LPS are not involved in *P. gingivalis*-mediated

363 regulation of Angpt1 and Angpt2 production in AoSMCs. *P. gingivalis* 381, DPG3,  
364 and KRX178 all down-regulate Angpt1 and up-regulate Angpt2 and ETS1 expression.  
365 In our previous study,<sup>25</sup> we found that the amount of LPS that was produced and  
366 released differed between various bacterial strains. Consequently, we studied how LPS  
367 produced by *P. gingivalis* affects Angpt1 and Angpt2 expression in AoSMCs. The  
368 results showed that LPS from *P. gingivalis* does not modulate the expression of  
369 Angpt1 or Angpt2 in AoSMCs. However, different acylated and phosphorylated  
370 isoforms of LPS have been reported to display different bioactivity,<sup>49</sup> which makes it  
371 difficult to compare outcomes when researchers use different isoforms of LPS.

372 TNF is a key regulator in the pathogenesis and progression of periodontitis and  
373 atherosclerosis. This cytokine plays crucial roles in the initiation and maintenance of  
374 immune responses to *P. gingivalis* infection.<sup>50-52</sup> TNF can induce the migration,  
375 proliferation and apoptosis of vascular smooth muscle cells.<sup>53</sup> Studies have shown  
376 that there is an association between plasma levels of Angpt2 and TNF in endotoxemia  
377 and sepsis patients.<sup>54, 55</sup> To study the role of TNF in the modulation of Angpt1 and  
378 Angpt2, we exposed AoSMCs to various doses of TNF. We found that TNF inhibited  
379 the expression of Angpt1 but increased the expression of Angpt2 in AoSMCs. These  
380 effects are similar to those obtained in AoSMCs that were stimulated with *P.*  
381 *gingivalis*. However, TNF was not detected in the supernatants of AoSMCs that were  
382 stimulated with *P. gingivalis*, which indicates that *P. gingivalis*-mediated regulation  
383 of Angpt1 and Angpt2 in AoSMCs is independent of TNF.

384 Because we found that *P. gingivalis* and TNF dramatically increase the expression of

385 the *Angpt2* gene in AoSMCs, we further examined the gene expression of ETS1, the  
386 transcription factor of *Angpt2*.<sup>56, 57</sup> Wild type, fimbriae mutant of *P. gingivalis*, and  
387 TNF increased the expression of the ETS1 gene, respectively, which was then  
388 correlated with the effects on *Angpt2*. However, the RgpA/B mutant E8 was unable to  
389 up-regulate ETS1 expression, which supports a role for Rgp in *P. gingivalis*-mediated  
390 regulation of *Angpt2* in AoSMCs. After knock down of ETS1 in AoSMCs, the  
391 up-regulation of *Angpt2* by *P. gingivalis* W50 was inhibited, which reveals that ETS1  
392 is critical for the induction of *Angpt2*.

393 To understand the regulatory role of *Angpt2* in AoSMCs, we treated AoSMCs with  
394 recombinant human *Angpt2*. *Angpt2* did not induce proliferation of AoSMCs, but it  
395 significantly induced the migration of the cells in a dose-dependent manner. During the  
396 progression of atherosclerosis, smooth muscle cells change from a contractile  
397 phenotype to a synthetic phenotype, and the migration of vascular smooth muscle cells  
398 in the intima layer marks a key event in the disease pathogenesis.<sup>58</sup> Several reports have  
399 shown that high levels of *Angpt2* are associated with atherosclerosis and coronary heart  
400 disease.<sup>59, 60</sup>

401 In summary, we found that *P. gingivalis* infection induces comparable effects on the  
402 expression of *Angpt1*, *Angpt2*, and ETS1 in AoSMCs, and gingipains are crucial for  
403 this regulation. However, the cardiovascular risk factor TNF is not involved. In  
404 combination with observed cellular effects, our findings suggest that *Angpt2* plays a  
405 role in the association between periodontitis and atherosclerosis.

406 **Conflict of interest:** none declared.

407

408

409

410

411

412

413

414

415

416

417

418

419

420 **Acknowledgements**

421 We are grateful to Prof. M. Curtis (Barts and The London, Queen Mary's School of  
422 Medicine and Dentistry, UK) for contributing the *P. gingivalis* wild type strain W50  
423 and its corresponding gingipain mutants (E8 and K1A) and to Prof. Genco RJ and Prof.  
424 Sharma A. (School of Dental Medicine, University at Buffalo, State University of New  
425 York, United States of America) for contributing the *P. gingivalis* wild type strain 381  
426 and its corresponding fimbriae mutants (DPG3 and KRX178). This work was  
427 supported by the Swedish Research Council for Medicine and Health (Grant No.  
428 2008-2459), the Swedish Heart and Lung Foundation (Grant No. T77414), the  
429 Foundation of Olle Engkvist, the Foundation of Mats Kleberg, and KK-stiftelsen.

430

431

432

433

434

435

436

437

438 **Figure legends**

439 **Fig. 1.** *P. gingivalis* and its gingipains regulate Angpt1 and Angpt2 expression in  
440 AoSMCs. Quantitative real-time PCR results demonstrate relative transcription levels  
441 for Angpt1 (A) and Angpt2 (B) in AoSMCs stimulated with 10 MOI of wild type *P.*  
442 *gingivalis* (ATCC 33077 and W50), Rgp mutant (E8), and Kgp mutant (K1A) for 2 h,  
443 8 h, 16 h, 24 h, and 48 h. All results were normalized to the gene expression level of the  
444 housekeeping gene GAPDH. Representative western blot showing Angpt2 protein  
445 expression levels of AoSMCs exposed to different *P. gingivalis* strains and *F. alocis* at  
446 10 MOI for 48 h (C). Quantification of Angpt2 protein expression levels by  
447 densitometry is shown in (D) for cells incubated for 48 h. Angpt2 density signals were  
448 normalized to GAPDH signal values. \*, p<0.05; \*\*, p<0.005; \*\*\*, p<0.0001. A, B,  
449 n=4-7; C-D, n=3.

450 **Fig. 2.** Fimbriae is not involved in *P. gingivalis*-mediated regulation of Angpt1 and  
451 Angpt2 production in AoSMCs. Quantitative real-time PCR results demonstrate  
452 relative transcription levels for Angpt1 (A) and Angpt2 (B) in AoSMCs stimulated with  
453 10 MOI of wild type *P. gingivalis* 381, major fimbriae mutant (DPG3), minor fimbriae  
454 mutant (KRX178), or medium containing 1 µg/ml of erythromycin (Control+EM) as a  
455 control for fimbriae mutants for 24 h. All results were normalized to the gene  
456 expression level of the housekeeping gene GAPDH. Statistically significant differences  
457 for the wild type *P. gingivalis* strain 381 are shown compared to the negative control.  
458 For fimbriae mutants, statistically significant differences are shown compared to group  
459 Control+EM. \*, p<0.05; \*\*, p<0.005. A, n=7; B, n=10.

460 **Fig. 3.** TNF regulates Angpt1 and Angpt2 expression in AoSMCs. Quantitative  
461 real-time PCR results demonstrate relative transcription levels for Angpt1 (A) and  
462 Angpt2 (B) of AoSMCs stimulated with 10 ng/ml or 50 ng/ml of TNF for 24 h or 48 h.  
463 All results were normalized to the gene expression level of the housekeeping gene  
464 GAPDH. Representative western blot showing Angpt2 protein expression levels in  
465 AoSMCs exposed to 10 ng/ml or 50 ng/ml of TNF for 48 h (C). Quantification of  
466 Angpt2 protein expression levels by densitometry is shown in (D). Angpt2 density  
467 signals were normalized to GAPDH signal values. \*,  $p<0.05$ ; \*\*,  $p<0.005$ ; \*\*\*,  
468  $p<0.0001$ . A, B,  $n=4$ ; C-D,  $n=3$ .

469 **Fig. 4.** *P. gingivalis* and its gingipains and fimbriae mutants up-regulate ETS1 in  
470 AoSMCs. Quantitative real-time PCR results demonstrate relative transcription levels  
471 of ETS1 in AoSMCs stimulated with 10 MOI of wild type ATCC 33277 and W50 and  
472 the W50 corresponding gingipain mutants (E8 and K1A) for 2 h, 8 h, 16 h, 24 h, and 48  
473 h (A), and wild type 381 and its corresponding fimbriae mutants (DPG3 and KRX178)  
474 of *P. gingivalis* for 24 h or TNF for 24 h and 48 h (C). All results were normalized to  
475 the gene expression level of the housekeeping gene GAPDH. Statistically significant  
476 differences for LPS and wild type *P. gingivalis* strain of 381 are compared to the  
477 negative control. For fimbriae mutants, statistically significant differences are  
478 compared to the group Control+EM. \*,  $p<0.05$ ; \*\*,  $p<0.005$ ; \*\*\*,  $p<0.0001$ . A,  $n=5$ ; B,  
479  $n=4$ ; C,  $n=7$ .

480 **Fig. 5.** *P. gingivalis* regulates Angpt2 through ETS1 in AoSMCs. AoSMCs were

481 treated with (KD) or without (Control) ETS1 siRNA or non-targeting siRNA (NT). The  
482 cells were then infected or not infected with *P. gingivalis* W50 for 24 h. Quantitative  
483 real-time PCR results demonstrate the relative transcription levels of ETS1 (A) and  
484 Angpt2 (B) in AoSMCs. The protein level of Angpt2 was determined by western blot  
485 (C) and the quantification of Angpt2 protein expression levels by densitometry is  
486 shown in (D). All results were normalized to the gene or protein expression level of  
487 GAPDH. Asterisks above W50 represent statistical comparisons to the negative  
488 control. \*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ; \*\*\*,  $p < 0.0001$ . A, B, C, D,  $n = 5$ .

489 **Fig. 6.** Angpt2 induces migration, but not proliferation, in AoSMCs. AoSMCs were  
490 treated with or without Angpt2 for 24 h. Then, the proliferation of the cells was  
491 measured using an MTT assay (A). The migration of AoSMCs after treatment with  
492 Angpt2 or DPBS (Control) was measured in a wound-healing assay. The photos were  
493 taken after wounding, at 0 h (as Control) and 18 h (B). The quantitative results were  
494 calculated by the reduction in the area of the wound after migration of the cells into the  
495 cell-free zone (C). \*\*,  $p < 0.005$ ; \*\*\*,  $p < 0.0001$ . A,  $n = 4$ ; B, C,  $n = 6$ .

496

497

498

499

500 **References**



- 501 1. **Tucka J, Yu H, Gray K, Figg N, Maguire J, Lam B, Bennett M, Littlewood T.**  
502 2014. Akt1 regulates vascular smooth muscle cell apoptosis through FoxO3a and  
503 Apaf1 and protects against arterial remodeling and atherosclerosis. *Arterioscler*  
504 *Thromb Vasc Biol* **34**:2421-8.
- 505 2. **Trollope AF, Golledge J.** 2011. Angiopoietins, abdominal aortic aneurysm and  
506 atherosclerosis. *Atherosclerosis* **214**:237-43.
- 507 3. **Sato TN, Qin Y, Kozak CA, Audus KL.** 1993. Tie-1 and tie-2 define another  
508 class of putative receptor tyrosine kinase genes expressed in early embryonic  
509 vascular system. *Proc Natl Acad Sci U S A* **90**:9355-8.
- 510 4. **Linares PM, Chaparro M, Gisbert JP.** 2014. Angiopoietins in inflammation and  
511 their implication in the development of inflammatory bowel disease. *J Crohns*  
512 *Colitis* **8**:183-90.
- 513 5. **Richey SL, Hutson TE.** 2013. Angiopoietins and non-vascular endothelial growth  
514 factor antiangiogenic targets in advanced renal cell carcinoma. *Cancer J.* 2013  
515 **19**:307-10.
- 516 6. **Eklund L, Olsen BR.** 2006. Tie receptors and their angiopoietin ligands are  
517 context-dependent regulators of vascular remodeling. *Exp Cell Res* **312**:630-41.
- 518 7. **Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD,**  
519 **McDonald DM.** 1999. Leakage-resistant blood vessels in mice transgenically  
520 overexpressing angiopoietin-1. *Science* **286**:2511-4.
- 521 8. **Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale**  
522 **NW, Witzenrath M, Rosseau S, Suttrop N, Sobke A, Herrmann M, Preissner**

- 523 **KT, Vajkoczy P, Augustin HG.** 2006. Angiopoietin-2 sensitizes endothelial cells  
524 to TNF-alpha and has a crucial role in the induction of inflammation. *Nat Med*  
525 **12:235-9.**
- 526 9. **Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO.** 2001. Direct  
527 cell adhesion to the angiopoietins mediated by integrins. *J Biol Chem*  
528 **276:26516-25.**
- 529 10. **Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I, Cheng SY.**  
530 2007. Angiopoietin-2 stimulates breast cancer metastasis through the  
531 alpha(5)beta(1) integrin-mediated pathway. *Cancer Res* **67:4254-63.**
- 532 11. **Yang HW, Huang YF, Chou MY.** 2004. Occurrence of *Porphyromonas*  
533 *gingivalis* and *Tannerella forsythensis* in periodontally diseased and healthy  
534 subjects. *J Periodontol* **75:1077-83.**
- 535 12. **Aruni AW, Zhang K, Dou Y, Fletcher H.** 2014. Proteome analysis of coinfection  
536 of epithelial cells with *Filifactor alocis* and *Porphyromonas gingivalis* shows  
537 modulation of pathogen and host regulatory pathways. *Infect Immun* **82:3261-74.**
- 538 13. **Schlafer S, Riep B, Griffen AL, Petrich A, Hübner J, Berning M, Friedmann**  
539 **A, Göbel UB, Moter A.** 2010. *Filifactor alocis*—involvement in periodontal  
540 biofilms. *BMC Microbiol* **10:66.**
- 541 14. **Kebschull M, Demmer RT, Papananou PN.** 2010. "Gum bug, leave my heart  
542 alone!"--epidemiologic and mechanistic evidence linking periodontal infections  
543 and atherosclerosis. *J Dent Res* **89:879-902.**
- 544 15. **Ogrendik M.** 2013. Rheumatoid arthritis is an autoimmune disease caused by

- 545 periodontal pathogens. *Int J Gen Med* **6**:383-6.
- 546 16. **Cavrini F, Sambri V, Moter A, Servidio D, Marangoni A, Montebuglioli L,**  
547 **Foschi F, Prati C, Di Bartolomeo R, Cevenini R.** 2005. Molecular detection of  
548 *Treponema denticola* and *Porphyromonas gingivalis* in carotid and aortic  
549 atheromatous plaques by FISH: report of two cases. *J Med Microbiol* **54**:93-6.
- 550 17. **Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ.** 2000. Identification  
551 of periodontal pathogens in atheromatous plaques. *J Periodontol* **71**:1554-60.
- 552 18. **Koizumi Y, Kurita-Ochiai T, Oguchi S, Yamamoto M.** 2008. Nasal  
553 immunization with *Porphyromonas gingivalis* outer membrane protein decreases P.  
554 *gingivalis*-induced atherosclerosis and inflammation in spontaneously  
555 hyperlipidemic mice. *Infect Immun* **76**:2958-65.
- 556 19. **Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck**  
557 **J, Madianos P, Sotres D, Chang YL, Koch G, Nichols TC.** 2005.  
558 *Porphyromonas gingivalis* bacteremia induces coronary and aortic atherosclerosis  
559 in normocholesterolemic and hypercholesterolemic pigs. *Arterioscler Thromb*  
560 *Vasc Biol* **25**:1446-51.
- 561 20. **Guo Y, Nguyen KA, Potempa J.** 2010. Dichotomy of gingipains action as  
562 virulence factors from cleaving substrates with the precision of surgeon's knife to a  
563 meat chopper like brutal degradation of proteins. *Periodontol 2000* **54**:15-44.
- 564 21. **Bostanci N, Belibasakis GN.** 2012. *Porphyromonas gingivalis*: an invasive and  
565 evasive opportunistic oral pathogen. *FEMS Microbiol Lett* **333**:1-9.
- 566 22. **Palm E, Khalaf H, Bengtsson T.** 2015. Suppression of inflammatory responses of

- 567 human gingival fibroblasts by gingipains from *Porphyromonas gingivalis*. *Mol*  
568 *Oral Microbiol.* **30**:74-85.
- 569 23. **Khalaf H, Lönn J, Bengtsson T.** 2014. Cytokines and chemokines are  
570 differentially expressed in patients with periodontitis: possible role for TGF- $\beta$ 1 as  
571 a marker for disease progression. *Cytokine* **67**:29-35.
- 572 24. **Nassar H, Chou HH, Khlgatian M, Gibson FC 3rd, Van Dyke TE, Genco CA.**  
573 2002. Role for fimbriae and lysine-specific cysteine proteinase gingipain K in  
574 expression of interleukin-8 and monocyte chemoattractant protein in  
575 *Porphyromonas gingivalis*-infected endothelial cells. *Infect Immun* **70**:268-76.
- 576 25. **Jayaprakash K, Khalaf H, Bengtsson T.** 2014. Gingipains from *Porphyromonas*  
577 *gingivalis* play a significant role in induction and regulation of CXCL8 in THP-1  
578 cells. *BMC Microbiol* **14**:193.
- 579 26. **Deshpande RG, Khan MB, Genco CA.** 1998. Invasion of aortic and heart  
580 endothelial cells by *Porphyromonas gingivalis*. *Infect Immun* **66**:5337-43.
- 581 27. **Kontani M, Kimura S, Nakagawa I, Hamada S.** 1997. Adherence of  
582 *Porphyromonas gingivalis* to matrix proteins via a fimbrial cryptic receptor  
583 exposed by its own arginine-specific protease. *Mol Microbiol* **24**:1179-87.
- 584 28. **Amar S, Wu SC, Madan M.** 2009. Is *Porphyromonas gingivalis* cell invasion  
585 required for atherogenesis? Pharmacotherapeutic implications. *J Immunol*  
586 **182**:1584-92.
- 587 29. **Jotwani R, Cutler CW.** 2004. Fimbriated *Porphyromonas gingivalis* is more  
588 efficient than fimbria-deficient *P. gingivalis* in entering human dendritic cells in

- 589 vitro and induces an inflammatory Th1 effector response. *Infect Immun*  
590 **72**:1725-32.
- 591 30. **Zhang B, Elmabsout AA, Khalaf H, Basic VT, Jayaprakash K, Kruse R,**  
592 **Sirsjö A.** 2013. The periodontal pathogen *Porphyromonas gingivalis* changes the  
593 gene expression in vascular smooth muscle cells involving the TGFbeta/Notch  
594 signalling pathway and increased cell proliferation. *BMC Genomics* **14**:770.
- 595 31. **Gomez D, Owens GK.** 2012. Smooth muscle cell phenotypic switching in  
596 atherosclerosis. *Cardiovasc Res* **95**:156-64.
- 597 32. **Bengtsson T, Karlsson H, Gunnarsson P, Skoglund C, Elison C, Leanderson**  
598 **P, Lindahl M.** 2008. The periodontal pathogen *Porphyromonas gingivalis* cleaves  
599 apoB and increases the expression of apoM in LDL in whole blood leading to cell  
600 proliferation. *J Intern Med* **263**:558-71.
- 601 33. **Nylander M, Lindahl TL, Bengtsson T, Grenegård M.** 2008. The periodontal  
602 pathogen *Porphyromonas gingivalis* sensitises human blood platelets to  
603 epinephrine. *Platelets* **19**:352-8.
- 604 34. **Engström KK, Khalaf H, Kälvegren H, Bengtsson T.** 2015. The role of  
605 *Porphyromonas gingivalis* gingipains in platelet activation and innate immune  
606 modulation. *Mol Oral Microbiol* **30**:62-73.
- 607 35. **Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM,**  
608 **Kriz W, Thurston G, Augustin HG.** 2004. The Tie-2 ligand angiopoietin-2 is  
609 stored in and rapidly released upon stimulation from endothelial cell  
610 Weibel-Palade bodies. *Blood* **103**:4150-6.

- 611 36. **Valentijn KM, van Driel LF, Mourik MJ, Hendriks GJ, Arends TJ, Koster**  
612 **AJ, Valentijn JA.** 2010. Multigranular exocytosis of Weibel-Palade bodies in  
613 vascular endothelial cells. *Blood* **116**:1807-16.
- 614 37. **David S, Kümpers P, Hellpap J, Horn R, Leitolf H, Haller H, Kielstein JT.**  
615 2009. Angiotensin 2 and cardiovascular disease in dialysis and kidney  
616 transplantation. *Am J Kidney Dis* **53**:770-8.
- 617 38. **Li C, Sun CJ, Fan JC, Geng N, Li CH, Liao J, Mi K, Zhu GQ, Ma H, Song**  
618 **YF, Tang YL, Chen Y.** 2013. Angiotensin-2 expression is correlated with  
619 angiogenesis and overall survival in oral squamous cell carcinoma. *Med Oncol*  
620 **30**:571
- 621 39. **Fawzy A, Gaafar R, Kasem F, Ali SS, Elshafei M, Eldeib M.** 2012. Importance  
622 of serum levels of angiotensin-2 and survivin biomarkers in non-small cell lung  
623 cancer. *J Egypt Natl Canc Inst* **24**:41-5.
- 624 40. **Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J.** 2001. Increased Tie2  
625 expression, enhanced response to angiotensin-1, and dysregulated angiotensin-2  
626 expression in hemangioma-derived endothelial cells. *Am J Pathol* **159**:2271-80.
- 627 41. **Post S, Peeters W, Busser E, Lamers D, Sluijter JP, Goumans MJ, de Weger**  
628 **RA, Moll FL, Doevendans PA, Pasterkamp G, Vink A.** 2008. Balance between  
629 angiotensin-1 and angiotensin-2 is in favor of angiotensin-2 in atherosclerotic  
630 plaques with high microvessel density. *J Vasc Res* **45**:244-50.
- 631 42. **Aruni AW, Roy F, Fletcher HM.** 2011. Filifactor alovis has virulence attributes  
632 that can enhance its persistence under oxidative stress conditions and mediate

- 633 invasion of epithelial cells by porphyromonas gingivalis. Infect Immun  
634 **79**:3872-86.
- 635 43. **Grenier D, Imbeault S, Plamondon P, Grenier G, Nakayama K, Mayrand D.**  
636 2001. Role of gingipains in growth of Porphyromonas gingivalis in the presence of  
637 human serum albumin. Infect Immun **69**:5166-72.
- 638 44. **Okamoto K, Nakayama K, Kadowaki T, Abe N, Ratnayake DB, Yamamoto**  
639 **K.** 1998. Involvement of a lysine-specific cysteine proteinase in hemoglobin  
640 adsorption and heme accumulation by Porphyromonas gingivalis. J Biol Chem  
641 **273**:21225-31.
- 642 45. **Nakayama K, Kadowaki T, Okamoto K, Yamamoto K.** 1995. Construction and  
643 characterization of arginine-specific cysteine proteinase (Arg-gingipain)-deficient  
644 mutants of Porphyromonas gingivalis. Evidence for significant contribution of  
645 Arg-gingipain to virulence. J Biol Chem **270**:23619-26.
- 646 46. **Kadowaki T, Nakayama K, Okamoto K, Abe N, Baba A, Shi Y, Ratnayake**  
647 **DB, Yamamoto K.** 2000. Porphyromonas gingivalis proteinases as virulence  
648 determinants in progression of periodontal diseases. J Biochem **128**:153-9.
- 649 47. **Kadowaki T, Yoneda M, Okamoto K, Maeda K, Yamamoto K.** 1994.  
650 Purification and characterization of a novel arginine-specific cysteine proteinase  
651 (argingipain) involved in the pathogenesis of periodontal disease from the culture  
652 supernatant of Porphyromonas gingivalis. J Biol Chem **269**:21371-8.
- 653 48. **Stathopoulou PG, Benakanakere MR, Galicia JC, Kinane DF.** 2009. The host  
654 cytokine response to Porphyromonas gingivalis is modified by gingipains. Oral

- 655 Microbiol Immunol **24**:11-7.
- 656 49. **Coats SR, Jones JW, Do CT, Braham PH, Bainbridge BW, To TT, Goodlett**  
657 **DR, Ernst RK, Darveau RP.** 2009. Human Toll-like receptor 4 responses to *P.*  
658 *gingivalis* are regulated by lipid A 1- and 4'-phosphatase activities. *Cell Microbiol*  
659 **11**:1587-99.
- 660 50. **Lin J, Bi L, Yu X, Kawai T, Taubman MA, Shen B, Han X.** 2014.  
661 *Porphyromonas gingivalis* exacerbates ligature-induced, RANKL-dependent  
662 alveolar bone resorption via differential regulation of Toll-like receptor 2 (TLR2)  
663 and TLR4. *Infect Immun* **82**:4127-34.
- 664 51. **Komatsu T, Nagano K, Sugiura S, Hagiwara M, Tanigawa N, Abiko Y,**  
665 **Yoshimura F, Furuichi Y, Matsushita K.** 2012. E-selectin mediates  
666 *Porphyromonas gingivalis* adherence to human endothelial cells. *Infect Immun*  
667 **80**:2570-6.
- 668 52. **Holden JA, Attard TJ, Laughton KM, Mansell A, O'Brien-Simpson NM,**  
669 **Reynolds EC.** 2014. *Porphyromonas gingivalis* lipopolysaccharide weakly  
670 activates M1 and M2 polarized mouse macrophages but induces inflammatory  
671 cytokines. *Infect Immun* **82**:4190-203.
- 672 53. **Kleinbongard P, Heusch G, Schulz R.** 2010. TNF $\alpha$  in atherosclerosis,  
673 myocardial ischemia/reperfusion and heart failure. *Pharmacol Ther* **127**:295-314.
- 674 54. **Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I,**  
675 **Sotiropoulou C, Zakyntinos S, Armaganidis A, Papapetropoulos A, Roussos**  
676 **C.** 2007. Angiopoietin-2 is increased in severe sepsis: correlation with



- 677 inflammatory mediators. *Crit Care Med* **35**:199-206.
- 678 55. **Kümpers P, van Meurs M, David S, Molema G, Bijzet J, Lukasz A, Biertz F,**  
679 **Haller H, Zijlstra JG.** 2009. Time course of angiotensin-2 release during  
680 experimental human endotoxemia and sepsis. *Crit Care* **13**:R64.
- 681 56. **Hasegawa Y, Abe M, Yamazaki T, Niizeki O, Shiiba K, Sasaki I, Sasaki I,**  
682 **Sato Y.** 2004. Transcriptional regulation of human angiotensin-2 by transcription  
683 factor Ets-1. *Biochem Biophys Res Commun* **316**:52-8.
- 684 57. **Oettgen P.** 2010. The role of ets factors in tumor angiogenesis. *J Oncol*  
685 **2010**:767384.
- 686 58. **Rudijanto A.** 2007. The role of vascular smooth muscle cells on the pathogenesis  
687 of atherosclerosis. *Acta Med Indones* **39**:86-93.
- 688 59. **David S, Kümpers P, Lukasz A, Kielstein JT, Haller H, Fliser D.** 2009.  
689 Circulating angiotensin-2 in essential hypertension: relation to atherosclerosis,  
690 vascular inflammation, and treatment with olmesartan/pravastatin. *J Hypertens*  
691 **27**:1641-7.
- 692 60. **David S, John SG, Jefferies HJ, Sigrist MK, Kümpers P, Kielstein JT, Haller**  
693 **H, McIntyre CW.** 2012. Angiotensin-2 levels predict mortality in CKD patients.  
694 *Nephrol Dial Transplant* **27**:1867-72.
- 695

Table 1. Primer sequences for real-time PCR

<b>Gene</b>	<b>Forward primer</b>	<b>Reverse primer</b>
<b>Angpt1</b>	CAACAGTGTCTTCAGAAGCAGC	CCAGCTTGATATACATCTGCACAG
<b>Angpt2</b>	ATTCAGCGACGTGAGGATGGCA	GCACATAGCGTTGCTGATTAGTC
<b>ETS1</b>	GAGTCAACCCAGCCTATCCAGA	GAGCGTCTGATAGGACTCTGTG
<b>GAPDH</b>	GTCTCCTCTGACTTCAACAGCG	ACCACCCTGTTGCTGTAGCCAA

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig.6

